+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Preimplantation Genetic Testing Market - Global Forecast 2026-2032- Product Image
Preimplantation Genetic Testing Market - Global Forecast 2026-2032- Product Image
Sale

Preimplantation Genetic Testing Market - Global Forecast 2026-2032

  • Report

  • 188 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968718
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Preimplantation Genetic Testing Market is projected to reach USD 981.15 Million in 2026. It is expected to continue growing at a CAGR of 12.36%, reaching USD 1.97 Billion by 2032.

Preimplantation genetic testing (PGT) has become a critical component of assisted reproductive technology (ART), enabling fertility centers to assess embryos for chromosomal aneuploidy, monogenic disorders, and structural rearrangements before embryo transfer. The field includes PGT-A for aneuploidy, PGT-M for monogenic disease, and PGT-SR for structural chromosomal rearrangements, with next-generation sequencing (NGS), polymerase chain reaction (PCR), single-nucleotide polymorphism (SNP) analysis, and whole-genome amplification supporting laboratory workflows.

Demand is underpinned by verified public-health and demographic indicators. The World Health Organization reports that around 1 in 6 adults experience infertility during their lifetime, while the CDC identifies age, genetics, reproductive history, and lifestyle-related factors as contributors to infertility risk. In this environment, PGT is increasingly positioned as a precision reproductive medicine tool that can support informed embryo selection, reduce the likelihood of transferring embryos affected by tested conditions, and help clinics align treatment decisions with patient-specific genetic risk.

Transformative Shifts in the PGT Landscape

The preimplantation genetic testing landscape is being reshaped by advances in NGS, improved embryo biopsy methods, vitrification, and integrated fertility-clinic data systems. Trophectoderm biopsy at the blastocyst stage has become widely used because it allows analysis of multiple cells while preserving the inner cell mass; however, professional guidance from organizations such as ASRM and ESHRE continues to emphasize careful counseling around mosaicism, test limitations, and embryo viability.

Another major shift is the movement from procedure-led fertility care toward evidence-led, patient-specific treatment planning. Clinics are placing greater emphasis on genetic counseling, laboratory accreditation, transparent reporting, and multidisciplinary review. At the same time, reimbursement gaps, uneven regulation, and ethical considerations around embryo testing continue to influence adoption across countries. Industry leaders that combine scientific rigor with patient education are better positioned to build trust in a sector where clinical accuracy and ethical transparency are central to long-term progress.

Cumulative Impact of Artificial Intelligence on PGT

Artificial intelligence is beginning to influence preimplantation genetic testing through embryo imaging analytics, laboratory quality control, workflow automation, and decision-support tools that combine embryology data with genomic findings. Time-lapse imaging and computer vision models can help standardize embryo morphology assessment, while AI-enabled lab systems can flag inconsistencies, track sample handling, and support chain-of-custody controls.

The cumulative impact of AI is likely to be operational before it is fully clinical. Peer-reviewed studies show that machine learning can improve consistency in embryo-grading tasks, but leading professional bodies continue to call for prospective validation before AI outputs are used as standalone clinical determinants. For PGT providers, the highest-value AI applications are therefore in reducing variability, improving turnaround times, enhancing lab documentation, and supporting explainable clinical decisions rather than replacing embryologists, geneticists, or reproductive endocrinologists.

Key Regional Insights: North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa

North America remains a highly developed PGT environment, led by the United States and Canada, where ART utilization, genetic counseling infrastructure, laboratory accreditation, and advanced sequencing capacity support broad clinical availability. The CDC’s national ART surveillance system and professional guidance from ASRM create a data-rich operating environment, although insurance coverage and state-level policy differences affect patient access. Europe is characterized by strong clinical governance and country-specific regulation, with the United Kingdom, Germany, France, Italy, and Spain applying different rules around embryo testing, storage, and permissible indications.

Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia invest in fertility services, genomic medicine, and private fertility networks. Delayed parenthood, increasing awareness of inherited disease risk, and improving access to NGS-based reproductive genetics are supporting adoption, while regulation and affordability remain uneven. Latin America, including Brazil and Mexico, shows rising demand through private fertility centers but faces affordability and regulatory variability. In the Middle East, GCC markets are supported by high healthcare investment and demand for genetic-disease prevention, particularly where carrier screening and consanguinity-related risk awareness are clinically relevant. Africa remains earlier-stage, with access concentrated in urban private fertility centers and constrained by cost, laboratory infrastructure, and specialist availability.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

The European Union is one of the most regulated groupings for PGT, with national health systems, data-protection rules, and ethics frameworks shaping access and clinical protocols. G7 markets collectively support innovation because they include major fertility-service economies, advanced sequencing infrastructure, and leading academic research centers. NATO membership overlaps with many high-income healthcare systems, supporting strong biomedical infrastructure, although PGT policy remains determined at the national level rather than by defense alliances.

BRICS countries are increasingly important to PGT adoption because China, India, and Brazil combine large patient populations with expanding fertility care and genomics capacity, while Russia and South Africa add regionally relevant clinical networks. ASEAN markets show uneven but rising adoption, supported by medical tourism hubs such as Singapore, Thailand, and Malaysia and by broader investment in specialty reproductive care. GCC countries are also strategically important because high per-capita healthcare spending, consanguinity-related genetic-disease awareness, and investment in specialty hospitals create a favorable environment for PGT-M and carrier-screening-linked IVF pathways.

Key Country Insights Across Major PGT Markets

The United States leads in commercial availability, laboratory scale, and integration of PGT into IVF practice, while Canada combines advanced clinical standards with more selective access pathways shaped by provincial healthcare structures. Mexico and Brazil are important Latin American markets where private fertility centers are expanding access to PGT, particularly for patients seeking advanced IVF services. In Europe, the United Kingdom benefits from HFEA oversight and transparent clinic reporting, Germany and France apply comparatively strict biomedical ethics frameworks, and Italy and Spain remain central to European fertility care, with Spain recognized for cross-border reproductive services. Russia maintains domestic fertility-service capacity, although geopolitical and economic conditions can affect cross-border demand and international collaboration.

China is expanding sequencing capacity and fertility infrastructure, India is growing through private IVF networks and medical tourism, Japan has strong clinical expertise but historically cautious regulation, Australia maintains high-quality ART oversight, and South Korea benefits from advanced medical technology adoption. Across all countries, adoption depends on the same fundamentals: patient affordability, regulation, laboratory quality, physician confidence, genetic counseling availability, and evidence-based communication of PGT benefits and limitations.

Actionable Recommendations for PGT Industry Leaders

Industry leaders should prioritize clinical evidence, transparent patient communication, and laboratory quality systems. PGT providers can strengthen competitiveness by investing in accredited NGS workflows, validated mosaicism reporting protocols, genetic counseling partnerships, and documented chain-of-custody controls. Clear communication is essential because PGT can reduce the risk of transferring embryos affected by tested abnormalities, but it does not guarantee pregnancy, live birth, or the absence of all genetic conditions.

Organizations should also build region-specific access strategies. In mature markets, differentiation should focus on turnaround time, reporting clarity, data security, and integration with IVF clinic software. In emerging markets, progress depends on clinician education, affordability models, local regulatory compliance, and partnerships with established fertility networks. AI should be deployed first in auditable, workflow-enhancing applications, with clinical claims reserved for tools supported by prospective validation and peer-reviewed evidence.

Research Methodology for PGT Intelligence

A robust PGT assessment should combine primary interviews with fertility specialists, embryologists, genetic counselors, laboratory directors, payers, and technology stakeholders with secondary research from verified sources such as WHO, CDC, ESHRE, ASRM, HFEA, national ART registries, peer-reviewed journals, patent databases, public filings, and regulatory publications. This approach supports evidence-based evaluation of demand drivers, technology adoption, clinical constraints, and competitive positioning without relying on unsupported claims.

Methodology should triangulate procedure volumes, IVF utilization, regulatory status, reimbursement indicators, laboratory capacity, and demographic factors such as maternal age trends and infertility prevalence. Intelligence should also assess PGT-A, PGT-M, and PGT-SR separately because each category has distinct clinical indications, evidence considerations, and patient decision pathways. Quality controls should include source validation, expert review, consistency checks, and exclusion of unverified statements.

Conclusion: Future of Preimplantation Genetic Testing

Preimplantation genetic testing is moving from a specialized IVF add-on toward a more integrated role in precision reproductive medicine. Momentum is supported by infertility prevalence, delayed parenthood, expanding genomic capabilities, and patient demand for clearer reproductive risk information. At the same time, the field’s credibility depends on rigorous validation, ethical practice, professional counseling, and responsible communication of clinical limitations.

The strongest opportunities will belong to providers that combine advanced sequencing, high-quality embryology, explainable data systems, and regionally compliant patient care. As AI, NGS, and digital laboratory platforms mature, PGT is expected to become more standardized, more data-driven, and more closely aligned with personalized fertility treatment planning.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Preimplantation Genetic Testing Market, by Test Type
7.1. Introduction
7.2. PGT-A (Aneuploidy)
7.3. PGT-M (Monogenic Disorders)
7.4. PGT-SR (Structural Rearrangements)
7.5. PGT-HLA (Human Leukocyte Antigen Matching)
8. Preimplantation Genetic Testing Market, by Technology Type
8.1. Introduction
8.2. Comparative Genomic Hybridization
8.3. Fluorescent In-Situ Hybridization
8.4. Next-Generation Sequencing
8.5. PCR-Based Testing
8.6. Single-Nucleotide Polymorphism
9. Preimplantation Genetic Testing Market, by Offering
9.1. Introduction
9.2. Instruments
9.3. Reagents & Consumables
9.3.1. Kits
9.3.2. Probes
10. Preimplantation Genetic Testing Market, by Procedure Stage
10.1. Introduction
10.2. Embryo Biopsy
10.3. Polar Body Biopsy
10.4. Blastocyst Biopsy
11. Preimplantation Genetic Testing Market, by Application
11.1. Introduction
11.2. Aneuploidy Screening
11.3. Monogenic Diseases
11.4. IVF Prognosis
12. Preimplantation Genetic Testing Market, by End User
12.1. Introduction
12.2. Diagnostic Laboratories
12.3. Fertility Clinics
12.4. Hospitals
12.5. Research Institutes
13. Preimplantation Genetic Testing Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Africa
13.5. Latin America
13.6. Middle East
14. Preimplantation Genetic Testing Market, by Group
14.1. NATO
14.2. G7
14.3. European Union
14.4. BRICS
14.5. ASEAN
14.6. GCC
15. Preimplantation Genetic Testing Market, by Country
15.1. United States
15.2. China
15.3. Germany
15.4. Japan
15.5. India
15.6. United Kingdom
15.7. France
15.8. Australia
15.9. Canada
15.10. Italy
15.11. South Korea
15.12. Brazil
15.13. Russia
15.14. Mexico
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Abbott Laboratories
17.2. Agilent Technologies, Inc.
17.3. Bio-Techne Corporation
17.4. Bioarray S.L.
17.5. EUROPE IVF International s.r.o.
17.6. F. Hoffmann-La Roche AG
17.7. Genea Limited
17.8. GENETiKS
17.9. Illumina, Inc.
17.10. Invicta Genetics
17.11. Invitae Corporation
17.12. Juno Genetics, US Inc.
17.13. Laboratory Corporation of America Holdings
17.14. MedGenome Labs Ltd.
17.15. Merck KGaA
17.16. Natera, Inc.
17.17. NextGen Genetics Holdings, LLC
17.18. Ovation Fertility
17.19. PacGenomics
17.20. PerkinElmer, Inc.
17.21. Progyny, Inc.
17.22. Qiagen N.V.
17.23. Quest Diagnostics Incorporated
17.24. Reproductive Genetic Innovations, LLC
17.25. SEQUENCE46, LLC
17.26. Sysmex Corporation
17.27. Takara Bio Inc.
17.28. The Cooper Companies Inc.
17.29. Thermo Fisher Scientific Inc.
17.30. Vitrolife Sweden AB
17.31. Yikon Genomics (Shanghai) Co., Ltd.
List of Figures
FIGURE 1. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025 VS 2032 (%)
FIGURE 11. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL PGT-A (ANEUPLOIDY) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL PGT-A (ANEUPLOIDY) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL PGT-A (ANEUPLOIDY) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL PGT-M (MONOGENIC DISORDERS) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL PGT-M (MONOGENIC DISORDERS) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL PGT-M (MONOGENIC DISORDERS) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL PGT-SR (STRUCTURAL REARRANGEMENTS) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL PGT-SR (STRUCTURAL REARRANGEMENTS) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL PGT-SR (STRUCTURAL REARRANGEMENTS) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL PGT-HLA (HUMAN LEUKOCYTE ANTIGEN MATCHING) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL PGT-HLA (HUMAN LEUKOCYTE ANTIGEN MATCHING) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL PGT-HLA (HUMAN LEUKOCYTE ANTIGEN MATCHING) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL COMPARATIVE GENOMIC HYBRIDIZATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL COMPARATIVE GENOMIC HYBRIDIZATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL COMPARATIVE GENOMIC HYBRIDIZATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL FLUORESCENT IN-SITU HYBRIDIZATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL FLUORESCENT IN-SITU HYBRIDIZATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL FLUORESCENT IN-SITU HYBRIDIZATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL PCR-BASED TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL PCR-BASED TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL PCR-BASED TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL SINGLE-NUCLEOTIDE POLYMORPHISM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL SINGLE-NUCLEOTIDE POLYMORPHISM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL SINGLE-NUCLEOTIDE POLYMORPHISM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL REAGENTS & CONSUMABLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL REAGENTS & CONSUMABLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL REAGENTS & CONSUMABLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL PROBES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL PROBES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL PROBES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL EMBRYO BIOPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL EMBRYO BIOPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL EMBRYO BIOPSY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL POLAR BODY BIOPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL POLAR BODY BIOPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL POLAR BODY BIOPSY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL BLASTOCYST BIOPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL BLASTOCYST BIOPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL BLASTOCYST BIOPSY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ANEUPLOIDY SCREENING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL ANEUPLOIDY SCREENING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL ANEUPLOIDY SCREENING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL MONOGENIC DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL MONOGENIC DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL MONOGENIC DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL IVF PROGNOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL IVF PROGNOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL IVF PROGNOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL FERTILITY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL FERTILITY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL FERTILITY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 81. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 83. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2017-2032 (USD MILLION)
TABLE 85. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 87. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 89. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 90. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 91. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 92. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2017-2032 (USD MILLION)
TABLE 93. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 94. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 95. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 97. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 98. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 99. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 100. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2017-2032 (USD MILLION)
TABLE 101. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 102. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 103. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 105. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 106. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 107. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 108. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2017-2032 (USD MILLION)
TABLE 109. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 110. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 111. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 113. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 114. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 115. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 116. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2017-2032 (USD MILLION)
TABLE 117. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 118. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 119. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 121. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 122. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 123. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 124. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2017-2032 (USD MILLION)
TABLE 125. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 126. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 128. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 129. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 130. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 131. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 132. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 133. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2017-2032 (USD MILLION)
TABLE 134. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 135. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 136. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 137. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 138. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 139. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 140. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 141. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2017-2032 (USD MILLION)
TABLE 142. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 143. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 144. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 145. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 146. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 147. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 148. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 149. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2017-2032 (USD MILLION)
TABLE 150. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 151. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 152. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 153. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 154. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 155. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 156. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 157. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2017-2032 (USD MILLION)
TABLE 158. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 159. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 160. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 161. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 162. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 163. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 164. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 165. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2017-2032 (USD MILLION)
TABLE 166. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 167. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 168. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 169. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 170. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 171. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 172. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 173. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2017-2032 (USD MILLION)
TABLE 174. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 175. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 176. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 177. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 178. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 179. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 180. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 181. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 182. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2017-2032 (USD MILLION)
TABLE 183. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 184. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 185. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 186. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 187. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 188. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 189. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 190. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2017-2032 (USD MILLION)
TABLE 191. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 192. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 193. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 194. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 195. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 196. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 197. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 198. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2017-2032 (USD MILLION)
TABLE 199. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 200. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 201. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 202. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 203. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 204. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 205. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 206. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2017-2032 (USD MILLION)
TABLE 207. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 208. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 209. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 210. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 211. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 212. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 213. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 214. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2017-2032 (USD MILLION)
TABLE 215. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 216. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 217. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 218. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 219. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 220. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 221. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 222. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2017-2032 (USD MILLION)
TABLE 223. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 224. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 225. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 226. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 227. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 228. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 229. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 230. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2017-2032 (USD MILLION)
TABLE 231. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 232. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 233. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 234. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 235. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 236. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 237. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 238. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2017-2032 (USD MILLION)
TABLE 239. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 240. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 241. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 242. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 243. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 244. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 245. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 246. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2017-2032 (USD MILLION)
TABLE 247. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 248. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 249. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 250. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 251. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 252. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 253. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 254. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2017-2032 (USD MILLION)
TABLE 255. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 256. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 257. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 258. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 259. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 260. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 261. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 262. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2017-2032 (USD MILLION)
TABLE 263. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 264. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 265. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 266. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 267. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 268. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 269. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 270. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2017-2032 (USD MILLION)
TABLE 271. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 272. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 273. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 274. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 275. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 276. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 277. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 278. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2017-2032 (USD MILLION)
TABLE 279. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 280. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 281. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 282. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 283. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 284. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 285. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 286. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2017-2032 (USD MILLION)
TABLE 287. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 288. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 289. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 290. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 291. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 292. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 293. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 294. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2017-2032 (USD MILLION)
TABLE 295. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 296. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 297. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2025
TABLE 298. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Bio-Techne Corporation
  • Bioarray S.L.
  • EUROPE IVF International s.r.o.
  • F. Hoffmann-La Roche AG
  • Genea Limited
  • GENETiKS
  • Illumina, Inc.
  • Invicta Genetics
  • Invitae Corporation
  • Juno Genetics, US Inc.
  • Laboratory Corporation of America Holdings
  • MedGenome Labs Ltd.
  • Merck KGaA
  • Natera, Inc.
  • NextGen Genetics Holdings, LLC
  • Ovation Fertility
  • PacGenomics
  • PerkinElmer, Inc.
  • Progyny, Inc.
  • Qiagen N.V.
  • Quest Diagnostics Incorporated
  • Reproductive Genetic Innovations, LLC
  • SEQUENCE46, LLC
  • Sysmex Corporation
  • Takara Bio Inc.
  • The Cooper Companies Inc.
  • Thermo Fisher Scientific Inc.
  • Vitrolife Sweden AB
  • Yikon Genomics (Shanghai) Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages188
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 981.15 Million
Forecasted Market Value ( USD ) by 2032 $ 1970 Million
Compound Annual Growth Rate12.3%
Regions CoveredGlobal
No. of Companies Mentioned31

Related Topics

Related Reports

Preimplantation Genetic Testing - Global Strategic Business Report - Product Image

Preimplantation Genetic Testing - Global Strategic Business Report

  • Report
  • 220 Pages
  • Global
From
Preimplantation Genetic Testing Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Preimplantation Genetic Testing Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 107 Pages
  • Global
From
Preimplantation Genetic Testing Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Preimplantation Genetic Testing Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Preimplantation Genetic Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

Preimplantation Genetic Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 177 Pages
  • Global
From
Preimplantation Genetic Testing Market by Product & Service, Technology, Procedure, Application, Type of Cycle - Global Forecast to 2030 - Product Image

Preimplantation Genetic Testing Market by Product & Service, Technology, Procedure, Application, Type of Cycle - Global Forecast to 2030

  • Report
  • 415 Pages
  • Global
From

About the Preimplantation Genetic Diagnosis Market

Preimplantation Genetic Diagnosis (PGD) is a biotechnology procedure used to detect genetic abnormalities in embryos prior to implantation. It is used in conjunction with in vitro fertilization (IVF) to help couples with a family history of genetic disorders or those at risk of transmitting a genetic disorder to their offspring. PGD involves the removal of a single cell from an embryo and testing it for genetic abnormalities. The results of the test are then used to determine which embryos are suitable for implantation. PGD has been used to detect a wide range of genetic disorders, including cystic fibrosis, Down syndrome, and Huntington's disease. It has also been used to detect chromosomal abnormalities, such as aneuploidy, which can lead to miscarriage or birth defects. PGD has been used to select embryos for gender selection, as well as to select embryos for tissue typing for bone marrow transplantation. Companies in the Preimplantation Genetic Diagnosis market include Illumina, Inc., Thermo Fisher Scientific, Inc., PerkinElmer, Inc., Agilent Technologies, Inc., and Natera, Inc. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.